APOC3 and metabolic dysfunction-associated steatohepatitis: Gemcabene 100 and 300 mg/kg -treated groups further and significantly reduced ApoC-III mRNA expression levels, by 29% and 43%, respectively, compared to vehicle-treated NASH group.